Publications by authors named "Jason Rusk"

Claim this Profile
A
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
Fred R Hirsch, Fairooz Kabbinavar, Tim Eisen, Renato Martins, Fredrick M Schnell, Jason Rusk

J Clin Oncol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
Glen J Weiss, Everett E Vokes, Paul A Bunn, Lyn Magree, Jason Rusk

J Thorac Oncol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of smoking on the pharmacokinetics of erlotinib.
Marta Hamilton, Julie L Wolf, Jason Rusk, Shannon E Beard, Gary M Clark

Clin Cancer Res· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
Michael V Seiden, Franco Muggia, Allan Astrow, Ursula Matulonis, Susanna Campos, Jason Rusk

Gynecol Oncol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study.
Ann F Mohrbacher, Stephanie A Gregory, Don A Gabriel, Jason M Rusk, Francis J Giles

Cancer· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis